Puma Biotechnology (PBYI) Competitors

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Which has more risk and volatility, PBYI or ADMA?

Puma Biotechnology has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Does the media refer more to PBYI or ADMA?

In the previous week, Puma Biotechnology had 9 more articles in the media than ADMA Biologics. MarketBeat recorded 12 mentions for Puma Biotechnology and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.54 beat Puma Biotechnology's score of 0.65 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer PBYI or ADMA?

Puma Biotechnology presently has a consensus price target of $7.00, indicating a potential upside of 95.80%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 51.25%. Given Puma Biotechnology's higher probable upside, analysts clearly believe Puma Biotechnology is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has stronger earnings & valuation, PBYI or ADMA?

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$230.50M	0.77	$30.28M	$0.77	4.64
ADMA Biologics	$426.45M	10.24	$197.67M	$0.85	21.52

Is PBYI or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Puma Biotechnology's net margin of 16.37%. Puma Biotechnology's return on equity of 49.35% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	16.37%	49.35%	18.25%
ADMA Biologics	45.01%	47.16%	30.51%

Do insiders and institutionals have more ownership in PBYI or ADMA?

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 23.3% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 17 factors compared between the two stocks.